Monthly archives for November, 2023
| Review of 9 Specialty Chemical Stocks And 3 Stock Recommendations by Axis Securities | |
| Company: | Speciality Chemicals stocks |
| Brokerage: | Axis Securities |
| Date of report: | November 26, 2023 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | Structural story of Indian Chemical industry remains strong with strategic portfolio composition to gain export market share, and strong domestic demand we expect revenue growth to gain momentum from FY25 onward. Given the changing landscape and growing reliance on India by international customers, we expect rapid growth in this sector over the coming period as conditions stabilize |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Axis Securities, Speciality Chemicals |
| Pharma is back on Growth Track. Axis Securities recommends 3 top picks in the Pharma universe | |
| Company: | Aurobindo Pharma |
| Brokerage: | Axis Securities |
| Date of report: | November 25, 2023 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | Q2FY24 Pharma Review – Higher Profitability with Easing Price Erosion, New Launches, and Lower RM Prices |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Model Portfolio |
| LIC: Upgrade to BUY – Undemanding valuation; structural issues priced-in: Emkay | |
| Company: | LIC |
| Brokerage: | Emkay |
| Date of report: | November 12, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 25% |
| Summary: | We upgrade the stock to BUY, as we believe higher surplus generation and slower growth could lead to a step jump in dividend, as solvency is healthy. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Emkay, LIC |
| PSP Projects has a sturdy foundation & promising future prospects. Buy for target price of Rs 905: SMIFS | |
| Company: | PSP Projects Ltd |
| Brokerage: | SMIFS |
| Date of report: | November 24, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 20% |
| Summary: | Additionally, well-managed balance sheet, strict working capital controls, and healthy return ratios are added positives. Given the favourable outlook, we initiate coverage with a Target Price of Rs905/share (15x Sept’25 estimated EPS), representing an upside potential of ~20% |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | PSP Projects Ltd, SMIFS |
| Royal Orchid Hotels will outpace peers & narrow valuation gap with its peers. Buy for target price of Rs 498 (76% upside): Nuvama | |
| Company: | Royal Orchid Hotels |
| Brokerage: | Nuvama |
| Date of report: | November 14, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 76% |
| Summary: | Strong room addition pipeline one of the key growth drivers. Expect revenue/EBITDA to clock 29%/18% CAGR over FY23–25 |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Nuvama, Royal Orchid Hotels |
| Impact of Increase in Risk Weights on Consumer Credit / Loans to NBFCs by Nirmal Bang | |
| Company: | Model Portfolio |
| Brokerage: | Nirmal Bang |
| Date of report: | November 17, 2023 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | Private banks have adequate capital buffers to grow comfortably |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Model Portfolio |
| Emudhra Ltd is seeing strong performance. Demand environment is strong. Buy for target price of Rs 556 (Yes Securities | |
| Company: | Emudhra |
| Brokerage: | Yes Securities |
| Date of report: | November 9, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 22.7% |
| Summary: | Strong performance led by expansion of the Enterprise business in foreign markets |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Emudhra |
| The BSE stock has rallied ~2.5x in the last six months led by market share gains. It is still a good buy for 22% upside: HDFC Sec | |
| Company: | BSE Ltd |
| Brokerage: | HDFC Sec |
| Date of report: | November 10, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 22% |
| Summary: | The stock has rallied ~2.5x in the last six months led by market share gains and is currently trading at a P/E of 37/30x FY25/26E vs 5Y average 1Y-fwd P/E ~21x |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | BSE, HDFC Sec |
| Hindware Home Innovation is a buy for target price of Rs 637 (34% upside): Nuvama | |
| Company: | Hindware Home Innovation |
| Brokerage: | Nuvama |
| Date of report: | November 10, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 34% |
| Summary: | From being a manufacturer of just one product, HINDWARE has grown significantly to gain market leadership in sanitary ware and is a major faucet ware player. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Hindware Home Innovation |
| Nifty is trading at a 12- month forward P/E of 17.6x, which is at a 13% discount to its 10-year average. Top 10 stocks to buy for up tp 38% upside by MOFSL | |
| Company: | Model Portfolio |
| Brokerage: | Motilal Oswal |
| Date of report: | November 11, 2023 |
| Type of Report: | Model Portfolio |
| Recommendation: | Buy |
| Upside Potential: | 38% |
| Summary: | Our last year’s Diwali picks have done well, with some of our ideas, such as L&T (+58%), IDFC First (+48%), Lemon Tree (+38%) generating superior returns compared to Nifty’s gain of 10% |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Model Portfolio, Motilal Oswal |